B47.9 Mycetoma, unspecified

Name of the Condition

• Mycetoma, unspecified

Summary

Mycetoma, unspecified is a chronic, progressive subcutaneous infection characterized by granulomatous tissue formation and sinus tract development. It affects the extremities, typically the feet, and is caused by either fungal (eumycetoma) or bacterial (actinomycetoma) organisms. The condition is endemic in tropical and subtropical regions and may lead to significant morbidity if untreated, including tissue destruction and deformity.

Causes

Mycetoma, unspecified is caused by either fungal or bacterial organisms. Eumycetoma results from fungi such as Madurella or Scedosporium, while actinomycetoma is caused by actinomycetes like Nocardia or Actinomadura. Infection occurs through traumatic inoculation of the organism into the skin, often via thorns or splinters, leading to localized tissue invasion and chronic inflammation.

Risk Factors

• Residence in or travel to endemic regions (e.g., parts of Africa, Asia, and Latin America).
• Occupational exposure to soil or organic matter, such as farming or walking barefoot.
• Traumatic skin injuries, particularly in contaminated environments.
• Immunocompromised states, including HIV/AIDS or diabetes, which may increase susceptibility to severe disease.

Symptoms

• Painless or mildly painful subcutaneous swelling, often on the foot or hand.
• Formation of sinus tracts draining serous or purulent fluid, sometimes containing grains (fungal or bacterial).
• Progressive tissue destruction and deformity over time.
• Limited range of motion in affected extremities.

Diagnosis

Diagnosis involves clinical evaluation, imaging (e.g., X-ray, MRI) to assess tissue involvement, and laboratory testing. Microscopic examination of sinus tract discharge may reveal characteristic grains. Tissue biopsy and culture help identify the causative organism (fungal or bacterial) and guide treatment. Histopathology confirms granulomatous inflammation.

Treatment Options

Treatment depends on the causative organism. Eumycetoma may require antifungal therapy (e.g., itraconazole) and surgery, while actinomycetoma often responds to antibiotics (e.g., sulfonamides, amoxicillin-clavulanate). Long-term therapy (months to years) is typical. Surgical debridement or amputation may be necessary for severe cases.

Prognosis and Follow-Up

Prognosis varies; early treatment improves outcomes, but delayed care can lead to permanent deformity or disability. Regular follow-up is essential to monitor response to therapy and detect recurrence. Chronic management may be needed for extensive disease.

Complications

• Severe tissue destruction and deformity.
• Loss of function in affected limbs.
• Secondary bacterial infections.
• Chronic pain or disability.

Lifestyle & Prevention

• Avoid walking barefoot in endemic areas.
• Wear protective footwear (e.g., sturdy shoes) in soil-rich environments.
• Clean and treat minor skin injuries promptly, especially in high-risk regions.
• Seek medical care for persistent swelling or drainage.

When to Seek Professional Help

Consult a healthcare provider if you experience:

• Persistent swelling, pain, or drainage in an extremity.
• Signs of infection (e.g., redness, warmth, fever).
• Worsening deformity or loss of function.
• Recent travel to or residence in endemic regions with new symptoms.

Tips for Medical Coders

Use B47.9 for cases of mycetoma where the specific type (eumycetoma or actinomycetoma) is not documented. Ensure clinical documentation supports the diagnosis, including details on location, chronicity, and any identified causative organisms if available. Verify that the code aligns with the patient’s clinical presentation and diagnostic findings.